Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550927 · ClinicalTrials.gov registry record · Phase 1
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00550927 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 42 participants.
The verdict
NCT00550927, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Enzastaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Enzastaurin and bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving enzastaurin together with bevacizumab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin and bevacizumab in treating patients with locally advanced or metastatic cancer.
Interventions
- OTHER pharmacological study
- BIOLOGICAL bevacizumab
- OTHER diagnostic laboratory biomarker analysis
- DRUG enzastaurin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550927
The ClinicalTrials.gov registry entry for NCT00550927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pharmacological study is the first listed.
NCT00550927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550927 about?
NCT00550927 is a clinical study titled "Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer". RATIONALE: Enzastaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill ...
What is the current status of trial NCT00550927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2006-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00550927?
The interventions under investigation include: pharmacological study (OTHER), bevacizumab (BIOLOGICAL), diagnostic laboratory biomarker analysis (OTHER), enzastaurin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00550927?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.